Barometer Capital Management Inc. Sells 87,222 Shares of Ascendis Pharma A/S $ASND

Barometer Capital Management Inc. cut its holdings in shares of Ascendis Pharma A/S (NASDAQ:ASND) by 95.4% during the 1st quarter, HoldingsChannel reports. The institutional investor owned 4,170 shares of the biotechnology company’s stock after selling 87,222 shares during the quarter. Barometer Capital Management Inc.’s holdings in Ascendis Pharma A/S were worth $954,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors also recently bought and sold shares of the business. Advisory Services Network LLC purchased a new position in Ascendis Pharma A/S in the 3rd quarter worth about $26,000. Arax Advisory Partners lifted its stake in Ascendis Pharma A/S by 212.2% during the 4th quarter. Arax Advisory Partners now owns 153 shares of the biotechnology company’s stock valued at $33,000 after acquiring an additional 104 shares during the period. Leonteq Securities AG purchased a new stake in shares of Ascendis Pharma A/S during the 4th quarter valued at about $36,000. Caitong International Asset Management Co. Ltd purchased a new stake in shares of Ascendis Pharma A/S during the 4th quarter valued at about $42,000. Finally, Global Retirement Partners LLC grew its stake in shares of Ascendis Pharma A/S by 111.9% in the fourth quarter. Global Retirement Partners LLC now owns 214 shares of the biotechnology company’s stock worth $46,000 after acquiring an additional 113 shares during the period.

Analyst Ratings Changes

Several research analysts have recently weighed in on ASND shares. Wedbush reissued an “outperform” rating and set a $273.00 price objective on shares of Ascendis Pharma A/S in a report on Thursday, April 9th. Citigroup initiated coverage on shares of Ascendis Pharma A/S in a report on Monday, May 18th. They issued a “buy” rating and a $355.00 target price on the stock. Royal Bank Of Canada lifted their target price on shares of Ascendis Pharma A/S from $275.00 to $280.00 and gave the stock an “outperform” rating in a research report on Tuesday, July 7th. Bank of America increased their price target on Ascendis Pharma A/S from $262.00 to $292.00 and gave the company a “buy” rating in a report on Thursday, April 16th. Finally, Barclays increased their price target on Ascendis Pharma A/S from $342.00 to $345.00 and gave the company an “overweight” rating in a report on Monday, May 11th. Two research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and one has given a Hold rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus price target of $295.67.

Ascendis Pharma A/S Price Performance

NASDAQ ASND opened at $255.20 on Wednesday. Ascendis Pharma A/S has a 52 week low of $160.86 and a 52 week high of $282.15. The firm has a market capitalization of $15.92 billion, a P/E ratio of 29.43 and a beta of 0.37. The company has a quick ratio of 0.72, a current ratio of 1.00 and a debt-to-equity ratio of 0.79. The company has a 50-day moving average price of $243.50 and a 200-day moving average price of $232.76.

Ascendis Pharma A/S (NASDAQ:ASND) last issued its quarterly earnings data on Thursday, May 7th. The biotechnology company reported $0.32 earnings per share for the quarter, topping the consensus estimate of $0.21 by $0.11. The business had revenue of $285.45 million during the quarter, compared to the consensus estimate of $362.47 million. Equities research analysts anticipate that Ascendis Pharma A/S will post 4.49 earnings per share for the current year.

Insider Buying and Selling

In other Ascendis Pharma A/S news, Director Jean Jacques Bienaime bought 400 shares of Ascendis Pharma A/S stock in a transaction on Tuesday, May 26th. The stock was acquired at an average cost of $237.80 per share, with a total value of $95,120.00. Following the completion of the acquisition, the director owned 400 shares in the company, valued at approximately $95,120. This represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Flemming Steen Jensen sold 19,460 shares of the stock in a transaction that occurred on Monday, May 11th. The stock was sold at an average price of $238.49, for a total transaction of $4,641,015.40. Additional details regarding this sale are available in the official SEC disclosure. 40.00% of the stock is currently owned by corporate insiders.

Ascendis Pharma A/S Profile

Ascendis Pharma A/S is a Denmark‐based biopharmaceutical company focused on developing innovative therapies for rare endocrine diseases. Founded in 2015 and headquartered in Hellerup, the company leverages its proprietary TransCon drug delivery platform to create long‐acting prodrugs designed to improve safety, efficacy and patient convenience. Ascendis Pharma maintains research and development operations in Europe and the United States, with clinical studies spanning North America, Europe and Asia.

The company’s lead product, lonapegsomatropin (Skytrofa®), is a once‐weekly growth hormone therapy approved by the U.S.